KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $106.8 million.

  • Neogenomics' Cost of Revenue rose 1275.45% to $106.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $413.0 million, marking a year-over-year increase of 1149.17%. This contributed to the annual value of $413.0 million for FY2025, which is 1149.17% up from last year.
  • As of Q4 2025, Neogenomics' Cost of Revenue stood at $106.8 million, which was up 1275.45% from $107.4 million recorded in Q3 2025.
  • Neogenomics' 5-year Cost of Revenue high stood at $107.4 million for Q3 2025, and its period low was $68.7 million during Q2 2021.
  • For the 5-year period, Neogenomics' Cost of Revenue averaged around $87.5 million, with its median value being $87.5 million (2023).
  • In the last 5 years, Neogenomics' Cost of Revenue soared by 2396.54% in 2021 and then surged by 174.59% in 2022.
  • Neogenomics' Cost of Revenue (Quarter) stood at $80.5 million in 2021, then increased by 1.75% to $81.9 million in 2022, then rose by 7.43% to $88.0 million in 2023, then grew by 7.71% to $94.7 million in 2024, then rose by 12.75% to $106.8 million in 2025.
  • Its Cost of Revenue stands at $106.8 million for Q4 2025, versus $107.4 million for Q3 2025 and $104.1 million for Q2 2025.